Literature DB >> 9610452

Dose uniformity of ophthalmic suspensions.

M Diestelhorst1, K A Kwon, R Süverkrup.   

Abstract

PURPOSE: To quantify the rate of redispersion of three commercially available ophthalmic preparations as well as the drug content of single drops during the course of emptying a full container of suspension eyedrops.
SETTING: Department of Ophthalmology, University of Köln, and Department of Pharmaceutical Technology, University of Bonn, Germany.
METHODS: In a computer-controlled test apparatus used to simulate the shaking and dropping behavior of humans under strictly reproducible conditions, we studied the rate of redispersion of three ophthalmic suspensions: 50 mg indomethacin, 50 mg prednisolone-21-acetate, and 50 mg dexamethasone in 5 mL of aqueous fluid. The degree of shaking intensity essential for the redispersion of the ophthalmic suspensions was quantified in healthy persons and patients by an acceleration sensor.
RESULTS: The mean dose delivered and the coefficient of variation of prednisolone were satisfactory. However, only 25% of the dexamethasone was available for administration; the rest remained in the bottle as a cake of sediment. Also, the variability of the drug content between drops was unacceptably high. The mean dose of indomethacin was adequate, but the between-drop variability was excessive.
CONCLUSION: The dose uniformity of suspension eyedrops depends on their homogeneity immediately before administration. Among the formulation factors studied, particle size appears to be the most important. The various redispersion rates of the three drugs underline their clinical profile.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9610452     DOI: 10.1016/s0886-3350(98)80264-2

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  7 in total

1.  [In vitro microstructural analysis of commercial ophthalmic suspensions by HRT II Rostock Cornea Module].

Authors:  L Imre; M Resch; M Megyesi; J Németh
Journal:  Ophthalmologe       Date:  2007-08       Impact factor: 1.059

2.  The role of difluprednate ophthalmic emulsion in clinical practice.

Authors:  Karim N Jamal; David G Callanan
Journal:  Clin Ophthalmol       Date:  2009-06-29

3.  Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%.

Authors:  William Stringer; Roy Bryant
Journal:  Clin Ophthalmol       Date:  2010-10-05

4.  Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%).

Authors:  Zora T Marlowe; Stephen R Davio
Journal:  Clin Ophthalmol       Date:  2013-12-10

5.  Apparent steroid resistance associated with prednisolone suspension.

Authors:  K P Sathe
Journal:  Indian J Nephrol       Date:  2014-05

Review 6.  Ophthalmic Nanoemulsions: From Composition to Technological Processes and Quality Control.

Authors:  Agnieszka Gawin-Mikołajewicz; Karol P Nartowski; Aleksandra J Dyba; Anna M Gołkowska; Katarzyna Malec; Bożena Karolewicz
Journal:  Mol Pharm       Date:  2021-09-17       Impact factor: 4.939

7.  Penetration of topically administered dexamethasone disodium phosphate and prednisolone acetate into the normal equine ocular fluids.

Authors:  Hanneke Hermans; Els M H van den Berg; Inge J M Slenter; Dax J C Vendrig; Lilian J L de Nijs-Tjon; Johannes C M Vernooij; Harold Brommer; Michael H Boevé; Ronette Gehring
Journal:  Equine Vet J       Date:  2021-11-21       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.